[Results of a controlled clinical study on a new retard antihypotensive agent with reference to Schellong's test].
D000605:Amino Alcohols / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007022:Hypotension / Q000188:drug therapy*; D007536:Isomerism; D008297:Male; D000442:Octanols / Q000009:adverse effects / Q000627:therapeutic use; D009655:Octopamine / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D000605:Amino Alcohols; D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D000442:Octanols; D010919:Placebos; D009655:Octopamine
Ergebnisse einer kontrollierten klinischen Prüfung eines neuen Retard-Antihypotonikums unter Berücksichtigung des Schellong-Verhaltens